Literature DB >> 2719769

Hepatic lipid peroxidation and aldehyde dehydrogenase activity in alcoholic and non alcoholic liver disease.

R Mazzanti1, S Moscarella, G Bensi, E Altavilla, P Gentilini.   

Abstract

It has been suggested that lipid peroxidation plays a role in the pathogenesis of chronic alcoholic liver disease (CALD). However, whether or not CALD differs from chronic non alcoholic liver disease (CLD) in lipid peroxidation, is still questionable. Thirty-eight patients affected by CALD and CLD who were matched for age, sex, nutrition and liver function tests (LFTs) and 17 controls (C) took part in this study. The following tests were performed: serum and liver malondialdehyde (MDA) determination by the TBA test, liver total glutathione (GSH) estimate, mitochondrial (ALDH2) and cytosolic (ALDH1) aldehyde dehydrogenase activity determinations. Patients who showed signs of malnutrition were excluded from this study. Serum and hepatic TBA-reactive substances resulted in a slight increase in chronic liver patients compared to controls but did not show any difference between CALD and CLD groups. Liver total glutathione did not show any change. Hepatic ALDH2 activity was significantly (P less than 0.01) higher in CALD than in CLD and control patients whereas ALDH1 did not show any difference. These results suggest that the increased lipid peroxidation in CALD and in CLD is probably secondary to liver damage rather than being the pathogenic factor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2719769     DOI: 10.1093/oxfordjournals.alcalc.a044875

Source DB:  PubMed          Journal:  Alcohol Alcohol        ISSN: 0735-0414            Impact factor:   2.826


  4 in total

1.  Increased ethane exhalation, an in vivo index of lipid peroxidation, in alcohol-abusers.

Authors:  P Lettéron; V Duchatelle; A Berson; B Fromenty; C Fisch; C Degott; J P Benhamou; D Pessayre
Journal:  Gut       Date:  1993-03       Impact factor: 23.059

2.  Monitoring oxidative damage in patients with liver cirrhosis and different daily alcohol intake.

Authors:  P Clot; M Tabone; S Aricò; E Albano
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

3.  Tryptophan in alcoholism treatment I: kynurenine metabolites inhibit the rat liver mitochondrial low Km aldehyde dehydrogenase activity, elevate blood acetaldehyde concentration and induce aversion to alcohol.

Authors:  Abdulla A-B Badawy; Samina Bano; Alex Steptoe
Journal:  Alcohol Alcohol       Date:  2011-09-06       Impact factor: 2.826

4.  Tryptophan in alcoholism treatment II: inhibition of the rat liver mitochondrial low Km aldehyde dehydrogenase activity, elevation of blood acetaldehyde concentration and induction of aversion to alcohol by combined administration of tryptophan and benserazide.

Authors:  Abdulla A-B Badawy; Samina Bano; Alex Steptoe
Journal:  Alcohol Alcohol       Date:  2011-09-06       Impact factor: 2.826

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.